<DOC>
	<DOCNO>NCT01148498</DOCNO>
	<brief_summary>The purpose trial compare average change amount amyloid beta specie blood infusion solanezumab .</brief_summary>
	<brief_title>A Biomarker Study Solanezumab Patients With Without Alzheimer 's</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Individuals Groups 1 , 2 , 3 , describe , participant longitudinal study memory age Washington University Alzheimer 's Disease Research Center ( WUADRC ) . These participant must result apolipoprotein E ( ApoE ) genotyping WUADRC . At begin study must 45 90 year age female childbearing potential , breastfeeding , test negative pregnancy , use medically accept form birth control time infusion 6 month afterward . Subjects must also meet criterion study group Group 1 , Mild dementia Alzheimer 's type ( DAT ) : Have mild DAT , determine Clinical Dementia Rating ( CDR ) 0.5 1 Have florbetapir PET image finding consistent underlie AD pathology . Group 2 , Older Adult Controls Possible AD Pathology : Have cognitive impairment indicate CDR rating 0 . Have possible AD pathology , determine florbetapir PET imaging . Group 3 , Older Adult Controls No Evidence AD Pathology : Have cognitive impairment indicate CDR rating 0 . Have evidence AD pathology determine florbetapir PET imaging . Individuals recruit Group 4 participant longitudinal study memory age WUADRC . To include Group 4 , individual must meet criterion : Are least 18 year &lt; 35 year age begin study female childbearing potential , breastfeeding , test negative pregnancy use highly effective contraception time solanezumab infusion 6 month follow infusion Have Folstein MiniMental State Examination ( MMSE ) score 29 30 beginning study Have previously complete withdrawn study study investigate solanezumab Does good venous access , intravenous drug delivery multiple blood draw would preclude Has allergy humanize monoclonal antibody Has know history human immunodeficiency virus ( HIV ) , clinically significant multiple severe drug allergy , severe posttreatment hypersensitivity reaction ( include , limited , erythema multiforme major , linear IgA dermatosis , toxic epidermal necrolysis , exfoliative dermatitis ) Has history chronic alcohol drug abuse/dependence Is clinically judge investigator serious risk suicide Has recent ( within 6 month screen ) current laboratory result ( available ) indicate clinically significant laboratory abnormality Has Electrocardiogram ( ECG ) abnormality obtain screening , opinion investigator , clinically significant regard subject 's participation study . Bazett 's correct QT [ QTcB ] interval must evaluate must exceed &gt; 458 msec male &gt; 474 msec female At screening , alanine transaminase ( ALT/SGPT ) value great equal 2 time upper limit normal ( ULN ) perform laboratory , aspartate transaminase ( AST/SGOT ) value great equal 3 time ULN , total bilirubin value great equal 2 time ULN Has IgG therapy ( sometimes call gamma globulin therapy ) within last year previous participation study investigate active immunization AÎ² Requires treatment monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>